Rahul Banarjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, recently wrote on his Twitter page:
“How do we standardize the standard of care for bortezomib (Velcade) in multiple myeloma?
Help us by filling out this 3-minute survey: redcap.link/velcade
So far >200 responses from 38 countries: many things we’ve learned about barriers to once-weekly V dosing!
Once-weekly or twice-weekly bortezomib in multiple myeloma: As bortezomib turns 20 years old, can we standardize the standard of care in terms of how it’s dosed? “
For details: Click here
Source: Rahul Banerjee / Twitter